[Postoperative interferon hydrogel treatment. A method for the successful therapy of chronic persistent giant condylomas in an immunologically deficient patient with Hodgkin's disease].
The local application of recombinant interferon alpha 2c hydrogel (1.10(6) I.U. recombinant interferon alpha 2c/g hydrogel) given as an adjuvant therapy after electrosurgery led to a complete cure, without relapse, of previously recalcitrant giant condylomata acuminata similar in appearance to Buschke-Löwenstein's tumors in a 19-year-old female patient suffering from Hodgkin's disease (stage II/III). Recombinant interferon alpha 2c hydrogel given as an adjuvant therapy to surgery may have more antiviral and antiproliferative effects than immunomodulating activities. This combined topical application form of interferon alpha is a safe and effective treatment, which is recommended especially in immunocompromised individuals suffering from genital HPV infection unresponsive to systemic interferon treatment or conventional therapy modalities.
Gross
G
G
Universitäts-Hautklinik Hamburg-Eppendorf.
Roussaki
A
A
Pfister
H
H
D000328:Adult; D001005:Anus Neoplasms / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D003218:Condylomata Acuminata / Q000601:surgery / Q000628:therapy*; D004564:Electrocoagulation; D005260:Female; D006689:Hodgkin Disease / Q000150:complications*; D006801:Humans; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate; D007153:Immunologic Deficiency Syndromes / Q000150:complications*; D007370:Interferon Type I / Q000008:administration & dosage*; D053685:Laser Therapy; D009364:Neoplasm Recurrence, Local / Q000601:surgery / Q000628:therapy*; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011994:Recombinant Proteins; D014846:Vulvar Neoplasms / Q000601:surgery / Q000628:therapy*
D007370:Interferon Type I; D011994:Recombinant Proteins; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate; D011092:Polyethylene Glycols
Die postoperative Interferon-Hydrogel-Behandlung. Methode zur erfolgreichen Therapie chronisch persistierender Riesenkondylome bei einer immundefekten Patientin mit Morbus Hodgkin.